Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies

Mar 05, 11:30 AM

Headliner
Share
Subscribe
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while AI partnerships and Pharma 4.0 technologies accelerate drug development and manufacturing efficiency.
Share
Subscribe
Next
Pharma Pulse: Eli Lilly’s Employer Connect Platform and Tandem Mobi Android Integration
Top episodes
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce